Open Access
Table 4.
Summary of the current literature after treatment of hip cartilage defects with ACI/MACI.
| Author | Design | Procedure | Patients (male/female) | Mean age (range) | Follow-up (months) | Score improvement (pre-post) | Defect size (cm2) | Localization | Grade | Additional treatment |
|---|---|---|---|---|---|---|---|---|---|---|
| Fontana et al. [15] | Retrospective study | ACI, Polymer-based scaffold BioSeed-C (BioTissue Technologies GmbH) | 15 (9/6) | 40.7 (22–52) | 73.8 (72–76) | HHS 39.4 | 2.6 | A (n = 15) FH (n = 3) | Outerbridge 3–4 | Not mentioned |
| Fickert et al. [14] | Case series | MACI, Chondrosphere (CO.DON®) | 6 (5/1) | 33 (25–45) | 11.2 | mHHS 23.5 NAHS 28.1 | 3.6 | A (n = 5) FH (n = 1) | ICRS IIIA–IIB | LR 3 LPR 2 |
| Körsmeier et al. [16] | Case series | MACI, Chondrosphere (CO.DON®) | 16 (14/2) | 31.8 (20–47) | 16.1 (10–29) | NAHS 26 WOMAC 33 | 4.5 | A (n = 16) | Outerbridge 3–4 | LR 2 LPR 4 |
| Schroeder et al. [17] | Case series | MACI, Chondrosphere (CO.DON®) | 20 (16/4) | 33 (22–49) | 12.1 (6–24) | mHHS 30 iHOT33 35% SHV 22% | 5.1 | A (n = 20) | Full-thickness defects | LR 18 |
| Fontana and de Girolamo [33] | Case series | ACI, Polymer-based scaffold BioSeed®-C (BioTissue Technologies GmbH) vs. AMIC Chondro-Gide®, (Geistlich Pharma AG, Switzerland) | ACT 26 (12/14) AMIC 31 (13/18) | ACT 36 ± 9.3 AMIC 36.4 ± 10.3 | 60 | ACT mHHS 37.8 ± 5.9 AMIC mHHS 39.1 ± 5.9 | ACT 2.8 ± 0.7 AMIC 2.9 ± 0.8 | ACT A (n = 26) AMIC A (n = 31) | Outerbridge 3–4 | Not mentioned |
LR = Labrum Repair; LPR = Partial Resection Labrum; A = Acetabulum; FH = Femoral Head.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.